The Food and Drug Administration recently approved gene therapy to treat sickle cell disease among children ages 2 and older, which a Nashville doctor described as a medical milestone.
Learn how gene editing is transforming sickle cell disease treatment and why expanding access to younger children matters.
The 500,000-square-foot facility, designed as a global gene therapy manufacturing complex, spans a full city block along ...
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug ...
WKRN Nashville on MSN
FDA approves gene therapy for young children with sickle cell disease
In a major medical breakthrough, the FDA has approved a gene therapy for children with sickle cell disease.
HealthDay on MSN
FDA expands use of first sickle cell disease gene therapy for children as young as 2 years
The U.S. Food and Drug Administration has issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent ...
A new study describes a gene therapy strategy that uses the brain's own glymphatic transport system to distribute engineered viral vectors throughout the brain.
An 11-year-old boy from Türkiye is receiving care for Elevidys, a one-time gene therapy for Duchenne Muscular Dystrophy (DMD) ...
Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...
The National Institute on Aging of the National Institutes of Health has awarded a five-year grant initially worth $8.37 ...
Stem cell transplantation (also called bone marrow transplantation) and gene therapy are among the most powerful curative ...
Genespire, in collaboration with researchers at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), has today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results